The main objective of these meetings is to promote international collaboration in various clinical and research projects. This paper is the summary of the 2007 Ljubljana meeting, and offers an overview of the proposed projects. The technical and methodological details of the projects will be published on the forum’s web site (http://www.med.ub.es/MIMMUN/FORUM/STUDIES.HTM).
1 Eschwège V Darnige L Piette JC Boffa MC . European forum on antiphospholipid antibodies: report on the first meeting, 10–11 October 1997, Hôpital Saint-Louis, Paris. Lupus1998; 7: 439–444.
2.
2 Cervera R Font J Tincani A Boffa M . V meeting of the European forum on antiphospholipid antibodies. Autoimmun Rev2006; 5: 499–507.
3.
3 Hughes GR . Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed)1983; 287: 1088–1089.
4.
4 Shoenfeld Y Meroni PL Cervera R . Antiphospholipid syndrome dilemmas still to be solved: 2008 status. Ann Rheum Dis2008; 67: 438–442.
5.
5 Pierangeli SS Vega-Ostertag ME Raschi E . Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis2007; 66: 1327–1333.
6.
6 Tincani A . Immunological abnormalities in the antiphospholipid syndrome. In: R Asherson R Cervera J Piette Y Shoenfeld , (eds), The antiphospholipid syndrome ii: autoimmune thrombosis.Amsterdam, Elsevier; 2002. p. 271–284.
7.
7 Andreoli L Pregnolato F Burlingame RW . Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity. J Autoimmun2008; 30: 51–57.
8.
8 Alarcón-Riquelme ME . The genetics of systemic lupus erythematosus: understanding how SNPs confer disease susceptibility. Springer Semin Immunopathol2006; 28: 109–117.
9.
9 Blank M Krause I Fridkin M . Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest2002; 109: 797–804.
10.
10 Berlin T Zandman-Goddard G Blank M . Autoantibodies in nonautoimmune individuals during infections. Ann N Y Acad Sci2007; 1108: 584–593.
11.
11 Arnson Y Amital H Shoenfeld Y . Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis2007; 66: 1137–1142.
12.
12 Meroni PL di Simone N Testoni C D’Asta M Acaia B Caruso A . Antiphospholipid antibodies as cause of pregnancy loss. Lupus2004; 13: 649–652.
13.
13 Di Simone N Meroni PL D’Asta M Di Nicuolo F D’Alessio MC Caruso A . Pathogenic role of anti-beta2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. Hum Reprod Update2007; 13: 189–196.
14.
14 Holers VM Girardi G Mo L . Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med2002; 195: 211–220.
15.
15 Girardi G Berman J Redecha P . Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest2003; 112: 1644–1654.
16.
16 Girardi G Redecha P Salmon JE . Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med2004; 10: 1222–1226.
17.
17 Berman J Girardi G Salmon JE . TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol2005; 174: 485–490.
18.
18 Martinez de la Torre Y Buracchi C Borroni EM . Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci U S A2007; 104: 2319–2324.
19.
19 Stone S Pijnenborg R Vercruysse L . The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta2006; 27: 457–467.
20.
20 Shamonki JM; Salmon JE; Hyjek E; Baergen RN; . Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196: 167.e1–167.e5.
21.
21 Cavazzana I Nebuloni M Cetin I . Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process. J Autoimmun2007; 28: 160–164.
22.
22 de Laat B Derksen RHWM Urbanus RT de Groot PG . IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood2005; 105: 1540–1545.
23.
23 Iverson GM Victoria EJ Marquis DM . Anti-beta2 glycoprotein I (beta2-GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A1998; 95: 15542–15546.
24.
24 Ioannou Y Pericleous C Giles I Latchman DS Isenberg DA Rahman A . Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum2007; 56: 280–290.
25.
25 de Laat B Derksen RHWM van Lummel M Pennings MTT de Groot PG . Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood2006; 107: 1916–1924.
26.
26 Sherer Y Shoenfeld Y . Atherosclerosis. Ann Rheum Dis2002; 61: 97–99.
27.
27 Doria A Shoenfeld Y Wu R . Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis2003; 62: 1071–1077.
28.
28 Ames PRJ Margarita A Sokoll KB Weston M Brancaccio V . Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis2005; 64: 315–317.
29.
29 Matsuura E Kobayashi K Inoue K Lopez LR Shoenfeld Y . Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus2005; 14: 736–741.
30.
30 Roman MJ Shanker B Davis A . Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med2003; 349: 2399–2406.
31.
31 Cervera R . Coronary and valvular syndromes and antiphospholipid antibodies. Thromb Res2004; 114: 501–507.
32.
32 Amigo MC García-Torres R . Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: relationship to pathogenesis. Curr Rheumatol Rep2000; 2: 262–270.
33.
33 Ziporen L Goldberg I Arad M . Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus1996; 5: 196–205.
34.
34 Cucnik S Kveder T Krizaj I Rozman B Bozic B . High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis2004; 63: 1478–1482.
35.
35 Hughes GRV Khamashta MA . Seronegative antiphospholipid syndrome. Ann Rheum Dis2003; 62: 1127.
36.
36 Sorice M Griggi T Circella A . Detection of antiphospholipid antibodies by immunostaining on thin layer chromatography plates. J Immunol Methods1994; 173: 49–54.
37.
37 Cervera R Bucciarelli S Espinosa G . Catastrophic antiphospholipid syndrome: lessons from the “CAPS Registry” – a tribute to the late Josep Font. Ann N Y Acad Sci2007; 1108: 448–456.
38.
38 Cervera R Espinosa G Bucciarelli S Gómez-Puerta JA Font J . Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry. Autoimmun Rev2006; 6: 81–84.
39.
39 Lyden TW Vogt E Ng AK Johnson PM Rote NS . Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J Reprod Immunol1992; 22: 1–14.
40.
40 Shurtz-Swirski R Inbar O Blank M Cohen J Bakimer R Shoenfeld Y . In vitro effect of anticardiolipin autoantibodies upon total and pulsatile placental hCG secretion during early pregnancy. Am J Reprod Immunol1993; 29: 206–210.
41.
41 Di Simone N Meroni PL de Papa N . Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum2000; 43: 140–150.
42.
42 Quenby S Mountfield S Cartwright JE Whitley GS Chamley L Vince G . Antiphospholipid antibodies prevent extravillous trophoblast differentiation. Fertil Steril2005; 83: 691–698.
43.
43 Kaider AS Kaider BD Janowicz PB Roussev RG . Immunodiagnostic evaluation in women with reproductive failure. Am J Reprod Immunol1999; 42: 335–346.
44.
44 Egbase PE Al Sharhan M Diejomaoh M Grudzinskas JG . Antiphospholipid antibodies in infertile couples with two consecutive miscarriages after in-vitro fertilization and embryo transfer. Hum Reprod1999; 14: 1483–1486.
45.
45 Sher G Fisch JD Maassarani G Matzner W Ching W Chong P . Antibodies to phosphatidylethanolamine and phosphatidylserine are associated with increased natural killer cell activity in non-male factor infertility patients. Hum Reprod2000; 15: 1932–1936.
46.
46 Carp H Toder V Aviram A Daniely M Mashiach S Barkai G . Karyotype of the abortus in recurrent miscarriage. Fertil Steril2001; 75: 678–682.
47.
47 Philipp T Philipp K Reiner A Beer F Kalousek DK . Embryoscopic and cytogenetic analysis of 233 missed abortions: factors involved in the pathogenesis of developmental defects of early failed pregnancies. Hum Reprod2003; 18: 1724–1732.
48.
48 Takakuwa K Asano K Arakawa M Yasuda M Hasegawa I Tanaka K . Chromosome analysis of aborted conceptuses of recurrent aborters positive for anticardiolipin antibody. Fertil Steril1997; 68: 54–58.
49.
49 Ogasawara M Aoki K Okada S Suzumori K . Embryonic karyotype of abortuses in relation to the number of previous miscarriages. Fertil Steril2000; 73: 300–304.
50.
50 Ulcova-Gallova Z Krauz V Novakova P . Anti-phospholipid antibodies against phosphatidylinositol, and phosphatidylserine are more significant in reproductive failure than antibodies against cardiolipin only. Am J Reprod Immunol2005; 54: 112–117.
51.
51 Boffa M Lachassinne E . Infant perinatal thrombosis and antiphospholipid antibodies: a review. Lupus2007; 16: 634–641.
52.
52 McAllister DL Kaplan BJ Edworthy SM . The influence of systemic lupus erythematosus on fetal development: cognitive, behavioral, and health trends. J Int Neuropsychol Soc1997; 3: 370–376.
53.
53 Ross G Sammaritano L Nass R Lockshin M . Effects of mothers’ autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch Pediatr Adolesc Med2003; 157: 397–402.
54.
54 Neri F Chimini L Bonomi F . Neuropsychological development of children born to patients with systemic lupus erythematosus. Lupus2004; 13: 805–811.
55.
55 Nacinovich R Galli J Bomba M . Neuropsychological development of children born to patients with antiphospholipid syndrome. Arthritis Rheum2008; 59: 345–351.
56.
56 Levy M Montes De Oca M Babron MC . [Incidence of lupus erythematosus disseminatus in children in Parisian region] Presse Med1989; 18: 2022.
57.
57 Avcin T Benseler SM Tyrrell PN Cucnik S Silverman ED . A follow-up study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum2008; 59: 206–213.
58.
58 Brunner HI Silverman ED To T Bombardier C Feldman BM . Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum2002; 46: 436–444.
59.
59 Ravelli A Caporali R Di Fuccia G Zonta L Montecucco C Martini A . Anticardiolipin antibodies in pediatric systemic lupus erythematosus. Arch Pediatr Adolesc Med1994; 148: 398–402.
60.
60 Levy M de Oca MM Wechsler B . [Systemic lupus erythematosus of paediatric onset: long-term follow-up of a cohort including 104 patients (1975–1985)] Arch Pediatr2004; 11: 503–506.
61.
61 Campos LMA Kiss MH D’Amico EA Silva CAA . Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus. Lupus2003; 12: 820–826.
62.
62 Descloux E Durieu I Cochat P . Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies. Rheumatology (Oxford)2008; 47: 183–187.
63.
63 Avcin T Silverman ED . Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus2007; 16: 627–633.
64.
64 Avcin T Cimaz R Meroni PL . Do we need an international consensus statement on classification criteria for the antiphospholipid syndrome in the paediatric population. Lupus2001; 10: 897–898.
